AR126009A1 - Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam - Google Patents
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcamInfo
- Publication number
- AR126009A1 AR126009A1 ARP220101435A ARP220101435A AR126009A1 AR 126009 A1 AR126009 A1 AR 126009A1 AR P220101435 A ARP220101435 A AR P220101435A AR P220101435 A ARP220101435 A AR P220101435A AR 126009 A1 AR126009 A1 AR 126009A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- cdr
- antigen
- binding
- region
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 title abstract 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 title abstract 4
- 102000012804 EPCAM Human genes 0.000 title 1
- 101150084967 EPCAM gene Proteins 0.000 title 1
- 101150057140 TACSTD1 gene Proteins 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 6
- 102000010910 CD28 Antigens Human genes 0.000 abstract 5
- 108010062433 CD28 Antigens Proteins 0.000 abstract 5
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 abstract 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención se refiere a moléculas agonistas biespecíficas de unión al antígeno CD28 caracterizadas por la unión monovalente a CD28 que comprenden nuevos anticuerpos contra EpCAM humanizados, procedimientos para su producción, composiciones farmacéuticas que contienen estos anticuerpos y procedimientos de uso de los mismos. Reivindicación 1: Una molécula agonista biespecífica de unión al antígeno CD28 caracterizada porque la unión a CD28 es monovalente, que comprende (a) un primer dominio de unión al antígeno que puede unirse específicamente a CD28, (b) un segundo dominio de unión al antígeno que puede unirse específicamente a un dominio de unión al antígeno que puede unirse específicamente a la molécula de adhesión de células epiteliales (EpCAM), y (c) un dominio Fc compuesto de una primera y una segunda subunidad que pueden asociarse establemente que comprende una o más sustituciones aminoacídicas que reducen la afinidad de unión de la molécula de unión al antígeno a un receptor Fc y/o función efectora, en la que dicho segundo dominio de unión al antígeno que puede unirse específicamente a EpCAM comprende (i) una región variable de la cadena pesada (VHEpCAM) que comprende una región determinante de la complementariedad de la cadena pesada CDR-H1 de SEQ ID Nº 309, una CDR-H2 de SEQ ID Nº 310 y una CDR-H3 de SEQ ID Nº 311, y una región variable de la cadena ligera (VLEpCAM) que comprende una región determinante de la complementariedad de la cadena ligera CDR-L1 de SEQ ID Nº 312 o SEQ ID NO:313, una CDR-L2 de SEQ ID Nº 314 y una CDR-L3 de SEQ ID Nº 315; o (ii) una región variable de la cadena pesada (VHEpCAM) que comprende una región determinante de la complementariedad de la cadena pesada CDR-H1 de SEQ ID Nº 2, una CDR-H2 de SEQ ID Nº 3 y una CDR-H3 de SEQ ID Nº 4, y una región variable de la cadena ligera (VLEpCAM) que comprende una región determinante de la complementariedad de la cadena ligera CDR-L1 de SEQ ID Nº 5, una CDR-L2 de SEQ ID Nº 6 y una CDR-L3 de SEQ ID Nº 7; o (iii) una región variable de la cadena pesada (VHEpCAM) que comprende una región determinante de la complementariedad de la cadena pesada CDR-H1 de SEQ ID Nº 10, una CDR-H2 de SEQ ID Nº 11 y una CDR-H3 de SEQ ID Nº 12, y una región variable de la cadena ligera (VLEpCAM) que comprende una región determinante de la complementariedad de la cadena ligera CDR-L1 de SEQ ID Nº 13, una CDR-L2 de SEQ ID Nº 14 y una CDR-L3 de SEQ ID Nº 15. Reivindicación 27: Un procedimiento de producción de una molécula agonista biespecífica de unión al antígeno CD28, caracterizado porque comprende las etapas de a) cultivar la célula huésped de la reivindicación 26 en condiciones adecuadas para la expresión de la molécula agonista biespecífica de unión al antígeno CD28 y b) opcionalmente recuperar la molécula agonista biespecífica de unión al antígeno CD28.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21177363 | 2021-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR126009A1 true AR126009A1 (es) | 2023-08-30 |
Family
ID=76250186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101435A AR126009A1 (es) | 2021-06-02 | 2022-05-31 | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4347649A1 (es) |
CN (1) | CN117480185A (es) |
AR (1) | AR126009A1 (es) |
TW (1) | TW202307008A (es) |
WO (1) | WO2022253867A1 (es) |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US7993650B2 (en) | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
PT2171060E (pt) | 2004-11-11 | 2013-11-18 | Theramab Llc | Anticorpo anti-cd28 superagonista |
DK1871805T3 (da) | 2005-02-07 | 2019-12-02 | Roche Glycart Ag | Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf |
BRPI0620632A2 (pt) | 2005-12-21 | 2011-12-20 | Micromet Ag | composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição farmacêuticas, e kits |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
UA113712C2 (xx) | 2010-08-13 | 2017-02-27 | Антитіло до fap і способи його застосування | |
DK2691417T3 (en) | 2011-03-29 | 2018-11-19 | Roche Glycart Ag | ANTIBODY FC VARIANTS |
EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
WO2014165818A2 (en) * | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP3209684B1 (en) | 2014-10-24 | 2020-12-23 | F.Hoffmann-La Roche Ag | Vh-vl-interdomain angle based antibody humanization |
CN117050176A (zh) | 2017-07-31 | 2023-11-14 | 豪夫迈·罗氏有限公司 | 基于三维结构的人源化方法 |
JP2022514262A (ja) * | 2018-12-17 | 2022-02-10 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
EP3897715A1 (en) | 2018-12-19 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
US11608376B2 (en) | 2018-12-21 | 2023-03-21 | Hoffmann-La Roche Inc. | Tumor-targeted agonistic CD28 antigen binding molecules |
PE20221282A1 (es) | 2019-12-18 | 2022-09-05 | Hoffmann La Roche | Anticuerpos que se unen a hla-a2/mage-a4 |
-
2022
- 2022-05-31 AR ARP220101435A patent/AR126009A1/es unknown
- 2022-06-01 EP EP22731574.4A patent/EP4347649A1/en active Pending
- 2022-06-01 WO PCT/EP2022/064837 patent/WO2022253867A1/en active Application Filing
- 2022-06-01 CN CN202280038648.0A patent/CN117480185A/zh active Pending
- 2022-06-01 TW TW111120389A patent/TW202307008A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022253867A1 (en) | 2022-12-08 |
TW202307008A (zh) | 2023-02-16 |
EP4347649A1 (en) | 2024-04-10 |
CN117480185A (zh) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11421035B2 (en) | Stable antibody variable domain framework combinations and methods of use thereof | |
HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
JP2018533973A5 (es) | ||
RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
AR122761A1 (es) | Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28 | |
US11319371B2 (en) | Anti-CD3 antibodies | |
FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
JP2017522892A5 (es) | ||
PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
RU2010133547A (ru) | Анти-cldn антитела | |
JP2013091655A5 (es) | ||
AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
JP2020524510A5 (es) | ||
CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
RS53405B (en) | CXCR4 HUMANIZED ANTIBODIES FOR CANCER TREATMENT | |
GB2595379A (en) | Anti-BTLA antibodies | |
PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
PE20230408A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
WO2018224441A1 (en) | Novel anti-cd3 antibodies | |
PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
AR126009A1 (es) | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam | |
RU2010122044A (ru) | УЛУЧШЕННЫЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Nogo-А И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
PE20231300A1 (es) | Anticuerpos anti-notch2 y metodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |